Medicines Company's Request to Extend Blood Drug Patent Turned Down
For the Medicines Company, a respite from a multi-billion Dollar blunder proved to be very short-lived.
On Friday, the United States Patent and Trademark Office once again ended up denying the firm's request to extend the life of the patent it currently holds, that protects its foremost medicine, the blood thinner Angiomax.
Since 2001, Medicines has been unsuccessfully trying to undo an error, that happened when it marginally missed a 60-day deadline in placing a request for the patent extension. As the patent office refused to accept a late application, the patent is now scheduled to expire on the coming Tuesday, instead of in late 2014, as it was originally suppose to be.
However, on Tuesday, a federal judge sent in an order to the patent office to revise and re-look its rejection of the extension, hinting that the agency has already been too strict in interpreting the law with regards to the 60-day deadline.
Also, the judge, Claude M. Hilton of the United States District Court in Alexandria, Va., ordered the office to ensure that the patent is still in force while it is conducting its reconsideration.
By the time Friday rolled in, however, the patent office had already closed its review, informing the company that it would continue to stick with its previous decision.